Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

370 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study for the evaluation of the benefits of 1 st Trimester risk markers in detecting Early Onset Pre-eclampsia and the use of the Placental Growth factor(PIGF) as a potential marker for Trisomy 21 and other aneuploidies.

Aim of this prospective nonprofit study is to analyze the benefits of early onset pre eclampsia risk assessment in the 1st trimester (measuring biochemical markers \[PIGF\], blood pressure and Doppler ultrasound), and how the results can permit to modify or influence the course of the preeclampsia during the pregnancy. The investigators will also evaluate the potential use of the PIGF as a marker to improve the prenatal screening with the currently used nuchal translucency, serum Pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (fBhCG) parameters.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction

NCT01490489

Pre-eclampsia Intra-uterine Growth Retardation

COMPLETED NA

Role of Placental Growth Factor (PlGF) in the Management of Non-Severe Preeclampsia

NCT02373839

Pregnancy; Pre-eclampsia, Mild

UNKNOWN NA

Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester

NCT02990767

Pre-Eclampsia

UNKNOWN

Pre-Eclampsia And Growth Restriction: a Longitudinal Study

NCT02379832

Preeclampsia Severe Preeclampsia Fetal Growth Restriction +1 more

COMPLETED

Predicting Late-onset Preeclampsia at 10-14 Weeks of Pregnancy

NCT04075708

Preeclampsia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

study group

patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton pregnancy
* Nulliparous pregnancy
* Gestation age between 6.0-13.6 weeks by last menstrual period verified by ultrasound
* Blood sample provided at gestational age 6.0-13.6 weeks
* Informed Consent

Exclusion Criteria

* Multi-fetal pregnancy
* Primiparous or multiparous pregnancy
* Mental retardation or other mental disorders that impose doubts regarding the true patient's willingness to participate in the study
* Gestation age below 6.0 or above 13.6 weeks by last menstrual period verified by ultrasound.
* Lack of blood sample at the specified enrollment period
* Known major fetal anomaly or fetal demise
* Lack of demographic data

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes